Characterization and Application of Hard X-Ray Betatron Radiation Generated by Relativistic Electrons from a Laser-Wakefield Accelerator

The necessity for compact table-top x-ray sources with higher brightness, shorter wavelength and shorter pulse duration has led to the development of complementary sources based on laser-plasma accelerators, in contrast to conventional accelerators. Relativistic interaction of short-pulse lasers with underdense plasmas results in acceleration of electrons and in consequence in the emission of spatially coherent radiation, which is known in the literature as betatron radiation. In this article we report on our recent results in the rapidly developing field of secondary x-ray radiation generated by high-energy electron pulses. The betatron radiation is characterized with a novel setup allowing to measure the energy, the spatial energy distribution in the far-field of the beam and the source size in a single laser shot. Furthermore, the polarization state is measured for each laser shot. In this way the emitted betatron x-rays can be used as a non-invasive diagnostic tool to retrieve very subtle information of the electron dynamics within the plasma wave. Parallel to the experimental work, 3D particle-in-cell simulations were performed, proved to be in good agreement with the experimental results.Comment: 38 pages, 19 figures, submitted to the Journal of Plasma Physic

R-Flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids

Background: R-flurbiprofen, one of the enantiomers of flurbiprofen racemate, is inactive with respect to cyclooxygenase inhibition, but shows analgesic properties without relevant toxicity. Its mode of action is still unclear. Methodology/Principal Findings: We show that R-flurbiprofen reduces glutamate release in the dorsal horn of the spinal cord evoked by sciatic nerve injury and thereby alleviates pain in sciatic nerve injury models of neuropathic pain in rats and mice. This is mediated by restoring the balance of endocannabinoids (eCB), which is disturbed following peripheral nerve injury in the DRGs, spinal cord and forebrain. The imbalance results from transcriptional adaptations of fatty acid amide hydrolase (FAAH) and NAPE-phospholipase D, i.e. the major enzymes involved in anandamide metabolism and synthesis, respectively. R-flurbiprofen inhibits FAAH activity and normalizes NAPE-PLD expression. As a consequence, R-Flurbiprofen improves endogenous cannabinoid mediated effects, indicated by the reduction of glutamate release, increased activity of the anti-inflammatory transcription factor PPAR gamma and attenuation of microglia activation. Antinociceptive effects are lost by combined inhibition of CB1 and CB2 receptors and partially abolished in CB1 receptor deficient mice. R-flurbiprofen does however not cause changes of core body temperature which is a typical indicator of central effects of cannabinoid-1 receptor agonists. Conclusion: Our results suggest that R-flurbiprofen improves the endogenous mechanisms to regain stability after axonal injury and to fend off chronic neuropathic pain by modulating the endocannabinoid system and thus constitutes an attractive, novel therapeutic agent in the treatment of chronic, intractable pain